Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis. 2020

Alessandra Musella, and Antonietta Gentile, and Livia Guadalupi, and Francesca Romana Rizzo, and Francesca De Vito, and Diego Fresegna, and Antonio Bruno, and Ettore Dolcetti, and Valentina Vanni, and Laura Vitiello, and Silvia Bullitta, and Krizia Sanna, and Silvia Caioli, and Sara Balletta, and Monica Nencini, and Fabio Buttari, and Mario Stampanoni Bassi, and Diego Centonze, and Georgia Mandolesi
Department of Human Sciences and Quality of Life Promotion, University of Rome San Raffaele, 00166 Rome, Italy.

Future treatments of multiple sclerosis (MS), a chronic autoimmune neurodegenerative disease of the central nervous system (CNS), aim for simultaneous early targeting of peripheral immune function and neuroinflammation. Sphingosine-1-phosphate (S1P) receptor modulators are among the most promising drugs with both "immunological" and "non-immunological" actions. Selective S1P receptor modulators have been recently approved for MS and shown clinical efficacy in its mouse model, the experimental autoimmune encephalomyelitis (EAE). Here, we investigated the anti-inflammatory/neuroprotective effects of ozanimod (RPC1063), a S1P1/5 modulator recently approved in the United States for the treatment of MS, by performing ex vivo studies in EAE brain. Electrophysiological experiments, supported by molecular and immunofluorescence analysis, revealed that ozanimod was able to dampen the EAE glutamatergic synaptic alterations, through attenuation of local inflammatory response driven by activated microglia and infiltrating T cells, the main CNS-cellular players of EAE synaptopathy. Electrophysiological studies with selective S1P1 (AUY954) and S1P5 (A971432) agonists suggested that S1P1 modulation is the main driver of the anti-excitotoxic activity mediated by ozanimod. Accordingly, in vivo intra-cerebroventricular treatment of EAE mice with AUY954 ameliorated clinical disability. Altogether these results strengthened the relevance of S1P1 agonists as immunomodulatory and neuroprotective drugs for MS therapy.

UI MeSH Term Description Entries
D007189 Indans Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES. Indanones
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D009435 Synaptic Transmission The communication from a NEURON to a target (neuron, muscle, or secretory cell) across a SYNAPSE. In chemical synaptic transmission, the presynaptic neuron releases a NEUROTRANSMITTER that diffuses across the synaptic cleft and binds to specific synaptic receptors, activating them. The activated receptors modulate specific ion channels and/or second-messenger systems in the postsynaptic cell. In electrical synaptic transmission, electrical signals are communicated as an ionic current flow across ELECTRICAL SYNAPSES. Neural Transmission,Neurotransmission,Transmission, Neural,Transmission, Synaptic
D010069 Oxadiazoles Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms. Oxadiazole
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002490 Central Nervous System The main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges. Cerebrospinal Axis,Axi, Cerebrospinal,Axis, Cerebrospinal,Central Nervous Systems,Cerebrospinal Axi,Nervous System, Central,Nervous Systems, Central,Systems, Central Nervous
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004681 Encephalomyelitis, Autoimmune, Experimental An experimental animal model for central nervous system demyelinating disease. Inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5) Autoimmune Encephalomyelitis, Experimental,Encephalomyelitis, Allergic,Encephalomyelitis, Experimental Autoimmune,Allergic Encephalomyelitis,Allergic Encephalomyelitis, Experimental,Autoimmune Experimental Encephalomyelitis,Experimental Allergic Encephalomyelitis,Experimental Autoimmune Encephalomyelitis,Encephalomyelitis, Autoimmune Experimental,Encephalomyelitis, Experimental Allergic,Experimental Allergic Encephalomyelitides,Experimental Encephalomyelitis, Autoimmune
D005260 Female Females

Related Publications

Alessandra Musella, and Antonietta Gentile, and Livia Guadalupi, and Francesca Romana Rizzo, and Francesca De Vito, and Diego Fresegna, and Antonio Bruno, and Ettore Dolcetti, and Valentina Vanni, and Laura Vitiello, and Silvia Bullitta, and Krizia Sanna, and Silvia Caioli, and Sara Balletta, and Monica Nencini, and Fabio Buttari, and Mario Stampanoni Bassi, and Diego Centonze, and Georgia Mandolesi
July 2016, Stroke,
Alessandra Musella, and Antonietta Gentile, and Livia Guadalupi, and Francesca Romana Rizzo, and Francesca De Vito, and Diego Fresegna, and Antonio Bruno, and Ettore Dolcetti, and Valentina Vanni, and Laura Vitiello, and Silvia Bullitta, and Krizia Sanna, and Silvia Caioli, and Sara Balletta, and Monica Nencini, and Fabio Buttari, and Mario Stampanoni Bassi, and Diego Centonze, and Georgia Mandolesi
April 2021, Neuroscience letters,
Alessandra Musella, and Antonietta Gentile, and Livia Guadalupi, and Francesca Romana Rizzo, and Francesca De Vito, and Diego Fresegna, and Antonio Bruno, and Ettore Dolcetti, and Valentina Vanni, and Laura Vitiello, and Silvia Bullitta, and Krizia Sanna, and Silvia Caioli, and Sara Balletta, and Monica Nencini, and Fabio Buttari, and Mario Stampanoni Bassi, and Diego Centonze, and Georgia Mandolesi
April 2021, CNS drugs,
Alessandra Musella, and Antonietta Gentile, and Livia Guadalupi, and Francesca Romana Rizzo, and Francesca De Vito, and Diego Fresegna, and Antonio Bruno, and Ettore Dolcetti, and Valentina Vanni, and Laura Vitiello, and Silvia Bullitta, and Krizia Sanna, and Silvia Caioli, and Sara Balletta, and Monica Nencini, and Fabio Buttari, and Mario Stampanoni Bassi, and Diego Centonze, and Georgia Mandolesi
July 2015, CNS drugs,
Alessandra Musella, and Antonietta Gentile, and Livia Guadalupi, and Francesca Romana Rizzo, and Francesca De Vito, and Diego Fresegna, and Antonio Bruno, and Ettore Dolcetti, and Valentina Vanni, and Laura Vitiello, and Silvia Bullitta, and Krizia Sanna, and Silvia Caioli, and Sara Balletta, and Monica Nencini, and Fabio Buttari, and Mario Stampanoni Bassi, and Diego Centonze, and Georgia Mandolesi
July 2017, Neuroscience letters,
Alessandra Musella, and Antonietta Gentile, and Livia Guadalupi, and Francesca Romana Rizzo, and Francesca De Vito, and Diego Fresegna, and Antonio Bruno, and Ettore Dolcetti, and Valentina Vanni, and Laura Vitiello, and Silvia Bullitta, and Krizia Sanna, and Silvia Caioli, and Sara Balletta, and Monica Nencini, and Fabio Buttari, and Mario Stampanoni Bassi, and Diego Centonze, and Georgia Mandolesi
October 2017, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics,
Alessandra Musella, and Antonietta Gentile, and Livia Guadalupi, and Francesca Romana Rizzo, and Francesca De Vito, and Diego Fresegna, and Antonio Bruno, and Ettore Dolcetti, and Valentina Vanni, and Laura Vitiello, and Silvia Bullitta, and Krizia Sanna, and Silvia Caioli, and Sara Balletta, and Monica Nencini, and Fabio Buttari, and Mario Stampanoni Bassi, and Diego Centonze, and Georgia Mandolesi
January 2016, Mini reviews in medicinal chemistry,
Alessandra Musella, and Antonietta Gentile, and Livia Guadalupi, and Francesca Romana Rizzo, and Francesca De Vito, and Diego Fresegna, and Antonio Bruno, and Ettore Dolcetti, and Valentina Vanni, and Laura Vitiello, and Silvia Bullitta, and Krizia Sanna, and Silvia Caioli, and Sara Balletta, and Monica Nencini, and Fabio Buttari, and Mario Stampanoni Bassi, and Diego Centonze, and Georgia Mandolesi
September 2021, Lancet (London, England),
Alessandra Musella, and Antonietta Gentile, and Livia Guadalupi, and Francesca Romana Rizzo, and Francesca De Vito, and Diego Fresegna, and Antonio Bruno, and Ettore Dolcetti, and Valentina Vanni, and Laura Vitiello, and Silvia Bullitta, and Krizia Sanna, and Silvia Caioli, and Sara Balletta, and Monica Nencini, and Fabio Buttari, and Mario Stampanoni Bassi, and Diego Centonze, and Georgia Mandolesi
February 2011, Der Nervenarzt,
Alessandra Musella, and Antonietta Gentile, and Livia Guadalupi, and Francesca Romana Rizzo, and Francesca De Vito, and Diego Fresegna, and Antonio Bruno, and Ettore Dolcetti, and Valentina Vanni, and Laura Vitiello, and Silvia Bullitta, and Krizia Sanna, and Silvia Caioli, and Sara Balletta, and Monica Nencini, and Fabio Buttari, and Mario Stampanoni Bassi, and Diego Centonze, and Georgia Mandolesi
May 2013, Journal of the neurological sciences,
Copied contents to your clipboard!